Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Immune checkpoint blockade therapies targeting the PD-L1/PD-1 axis have demonstrated clear clinical benefits. Improved understanding of the underlying regulatory mechanisms might contribute new insights into immunotherapy. Here, we identify transmembrane and ubiquitin-like domain-containing protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Chengyu, Wang, Ying, Wu, Minjie, Chen, Yu, Liu, Fangzhou, Shen, Zheyuan, Wang, Yiran, Xie, Shaofang, Shen, Yingying, Sang, Lingjie, Zhang, Zhen, Gao, Zerui, Yang, Luojia, Qu, Lei, Yang, Zuozhen, He, Xinyu, Guo, Yu, Pan, Chenghao, Che, Jinxin, Ju, Huaiqiang, Liu, Jian, Cai, Zhijian, Yan, Qingfeng, Yu, Luyang, Wang, Liangjing, Dong, Xiaowu, Xu, Pinglong, Shao, Jianzhong, Liu, Yang, Li, Xu, Wang, Wenqi, Zhou, Ruhong, Zhou, Tianhua, Lin, Aifu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663433/
https://www.ncbi.nlm.nih.gov/pubmed/36376293
http://dx.doi.org/10.1038/s41467-022-34346-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663433/
https://www.ncbi.nlm.nih.gov/pubmed/36376293
http://dx.doi.org/10.1038/s41467-022-34346-x

Ejemplares similares